Incyte (INCY) fundamentals: P/E, valuation, undervalued?
Incyte · Health Care · ref. ETF XLV · price $108.62
In short — Incyte trades at 14.2× earnings (P/E), 12.5× forward, with a net margin of 27.7 % and revenue growth of +38 %. Read: Cheap for the growth (P/E 12 for ~38% growth (PEG 0.3)).
Is Incyte stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$108.62+26.4% over range
Oct 14, 25low $85.96 · high $129.93Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Hold
47% recommend buying · 17 analysts
Valuation : Cheap for the growth — P/E 12 for ~38% growth (PEG 0.3)
Valuation
14.2
P/E (price/earnings)
12.5
Forward P/E
0.38
PEG
3.4
Price/book (P/B)
$22.0B
Market cap
7.66
EPS
Profitability & growth
27.7 %
Net margin
+38 %
Revenue growth
+38 %
Earnings growth
$38M
Total debt
Incyte income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2022 | $3.4B | $341M | 10.0 % |
| 2023 | $3.7B | $598M | 16.2 % |
| 2024 | $4.2B | $33M | 0.8 % |
| 2025 | $5.1B | $1.3B | 25.0 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is Incyte's P/E and is the stock undervalued? What's a good P/E?
Incyte's P/E is 14.2 (forward 12.5). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Cheap for the growth".
Is Incyte profitable?
Incyte has a net margin of 27.7 % (EPS 7.66). The company is profitable.
Is INCY stock expensive?
Our read: "Cheap for the growth" — P/E 12 for ~38% growth (PEG 0.3). Cross-check with growth and sector.
💬 A question about Incyte? The JPI assistant answers using our backtest data.